MSN Laboratories Private Limited — Moxifloxacin Exporter Profile
Indian Pharmaceutical Exporter · #2 for Moxifloxacin · $2.3M export value · DGFT Verified
MSN Laboratories Private Limited is the #2 Indian exporter of Moxifloxacin with $2.3M in export value and 89 verified shipments. MSN Laboratories Private Limited holds a 7.0% market share in Moxifloxacin exports across 13 countries. The company exports 32 pharmaceutical products worth $252.1M across 15 therapeutic categories.
MSN Laboratories Private Limited — Moxifloxacin Export Profile: Buyers & Destinations
Where Does MSN Laboratories Private Limited Export Moxifloxacin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $1.0M | 30 | 52.4% |
| UNITED STATES | $291.7K | 10 | 15.0% |
| AUSTRALIA | $222.2K | 12 | 11.5% |
| UNITED KINGDOM | $179.3K | 6 | 9.2% |
| PERU | $45.4K | 5 | 2.3% |
| CHILE | $42.5K | 3 | 2.2% |
| MAURITIUS | $40.6K | 4 | 2.1% |
| TANZANIA | $29.3K | 10 | 1.5% |
| PAKISTAN | $27.3K | 1 | 1.4% |
| CAMBODIA | $17.0K | 1 | 0.9% |
MSN Laboratories Private Limited exports Moxifloxacin to 13 countries. The largest destination is NETHERLANDS accounting for 52.4% of MSN Laboratories Private Limited's Moxifloxacin shipments, followed by UNITED STATES (15.0%) and AUSTRALIA (11.5%). These destinations reflect MSN Laboratories Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Moxifloxacin from MSN Laboratories Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER OF | AUSTRALIA | $505.7K | 22 |
| I+SOLUTIONS | NETHERLANDS | $302.8K | 9 |
| I+ SOLUTIONS, | NETHERLANDS | $290.3K | 7 |
| NOVADOZ PHARMACEUTICALS LLC | UNITED STATES | $249.6K | 8 |
| APOTEX PTY LTD | AUSTRALIA | $121.1K | 8 |
| TILLOMED LABORATORIES LIMITED | UNITED KINGDOM | $112.1K | 4 |
| GDF TILBURG SRS D102TC | NETHERLANDS | $76.2K | 5 |
| I SOLUTIONS POLARNERBAAN | NETHERLANDS | $50.0K | 1 |
| MSN LABS PERU SAC | PERU | $45.4K | 5 |
| APORTEX PTY LTD | AUSTRALIA | $40.4K | 2 |
MSN Laboratories Private Limited supplies Moxifloxacin to 20 buyers globally. The largest buyer is TO THE ORDER OF (AUSTRALIA), followed by I+SOLUTIONS (NETHERLANDS) and I+ SOLUTIONS, (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Moxifloxacin Export Value and How Much Does MSN Laboratories Private Limited Contribute?
India exported $14.3M worth of Moxifloxacin through 2,413 shipments from 336 suppliers to 137 countries, serving 731 buyers globally. MSN Laboratories Private Limited contributes $2.3M to this total, accounting for 7.0% of India's Moxifloxacin exports. MSN Laboratories Private Limited ships Moxifloxacin to 13 countries through 20 buyers.
What Is the Average Shipment Value for MSN Laboratories Private Limited's Moxifloxacin Exports?
MSN Laboratories Private Limited's average Moxifloxacin shipment value is $25.9K per consignment, based on 89 shipments totaling $2.3M. The largest destination is NETHERLANDS (52.4% of MSN Laboratories Private Limited's Moxifloxacin exports).
How Does MSN Laboratories Private Limited Compare to Other Indian Moxifloxacin Exporters?
MSN Laboratories Private Limited ranks #2 among 336 Indian Moxifloxacin exporters with a 7.0% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($2.3M), MICRO LABS LIMITED ($2.3M), EUGIA PHARMA SPECIALITIES LIMITED ($1.9M). MSN Laboratories Private Limited processed 89 shipments to 13 destination countries.
What Moxifloxacin Formulations Does MSN Laboratories Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| FLOXSAFE 400MG(MOXIFLOXACIN 400MG)FCA +PFRC 10X10S | $240.3K | 6 |
| MSN PHARMACEUTICALS PRODUCT NAME FLOXSAFE 400MG MOXIFLOXACIN 400MG FCA PFRC10x10s | $132.9K | 4 |
| Moxifloxacin Tablets 400mg, 30s NDC: 72205-001-30 | $108.3K | 3 |
| MOXIFLOXACIN-APO TABLETS | $101.2K | 4 |
| FLOXSAFE 400MGMOXIFLOXACIN 400MGFCA +PFRC 10X10S | $82.9K | 2 |
| MOXIFLOXACIN FC TABS 400MG X 5 TILLOMED | $81.1K | 3 |
| MOXIFLOXACIN-APO TABLETS-MSN PHARMA | $60.3K | 6 |
| FLOXSAFE 400MG(MOXIFLOXACIN 400MG)FCA+PFRC 10 X 10S | $50.0K | 1 |
| FLOXSAFE 400MG(MOXIFLOXACIN 400MG)FCA +PFRC 10X10SNOS | $50.0K | 1 |
| FLOXSAFE 400MG(MOXIFLOXACIN 400MG)FCA +PFRC 10X10S BATCH NO- DRD11370A MFG DATE- NOV 2023 EXP DATE- OCT 2027NOS | $50.0K | 1 |
MSN Laboratories Private Limited exports 58 distinct Moxifloxacin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FLOXSAFE 400MG(MOXIFLOXACIN 400MG)FCA +PFRC 10X10S with 6 shipments worth $240.3K.
Regulatory Requirements: Exporting Moxifloxacin to Key Markets
What MSN Laboratories Private Limited must comply with to export Moxifloxacin to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does MSN Laboratories Private Limited Compare to Nearest Moxifloxacin Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | MSN LABORATORIES PRIVATE LIMITED ★ | $2.3M | 89 | 13 | $25.9K |
| 4 | MICRO LABS LIMITED | $2.3M | 86 | 14 | $26.5K |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED | $1.9M | 39 | 1 | $50.0K |
MSN Laboratories Private Limited ranks #2 among 336 Indian Moxifloxacin exporters. Average shipment value of $25.9K compared to the market average of $42.4K. The closest competitors by value are MICRO LABS LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Moxifloxacin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 311 | 12.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 263 | 10.9% |
| DELHI AIR CARGO ACC (INDEL4) | 152 | 6.3% |
| DELHI AIR | 132 | 5.5% |
| NHAVA SHEVA SEA (INNSA1) | 126 | 5.2% |
| Bombay Air | 119 | 4.9% |
| CHENNAI AIR | 111 | 4.6% |
| CHENNAI AIR CARGO ACC (INMAA4) | 93 | 3.9% |
Geopolitical & Trade Policy Impact on MSN Laboratories Private Limited's Moxifloxacin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like MSN Laboratories. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major shipping lines to alter routes. This has resulted in extended transit times by 10–20 days and a 40–50% increase in freight rates on key India–Europe routes, impacting the timely delivery of pharmaceutical products. (livemint.com)
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the imposition of tariffs on Indian pharmaceutical products poses a risk to export volumes, as higher tariffs can lead to increased costs and reduced competitiveness in the US market. (orfonline.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) requires stringent serialization and traceability measures. For companies like MSN Laboratories, adhering to these regulations is crucial to maintain market access and ensure the integrity of their supply chain.
MSN Laboratories Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practice (EU GMP) guidelines set rigorous quality benchmarks. Any lapses can lead to import bans, product recalls, and reputational damage.
MSN Laboratories' recent legal challenges, such as the patent litigation with Exelixis, Inc., highlight the importance of robust regulatory and intellectual property strategies. Ensuring compliance with evolving quality requirements and proactively addressing regulatory challenges are essential for sustaining export growth and market credibility.
About MSN Laboratories Private Limited
MSN Laboratories Private Limited exports 32 products worth $252.1M. Beyond Moxifloxacin, top products include Atorvastatin, Rosuvastatin, Ras, Oseltamivir, Calcium. View the complete MSN Laboratories Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Moxifloxacin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Moxifloxacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: MSN Laboratories Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 89 individual customs records matching MSN Laboratories Private Limited exporting Moxifloxacin, covering 58 formulations to 13 countries via 20 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 137+ countries, 731+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Moxifloxacin Export Data from MSN Laboratories Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for MSN Laboratories Private Limited's Moxifloxacin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
MSN Laboratories Private Limited
Full Company Profile →
32 products · $252.1M total trade · 15 categories
Moxifloxacin Stats
Company Overview
Top Products by MSN Laboratories Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for MSN Laboratories Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Moxifloxacin. For current shipment-level data, contact TransData Nexus.